Ann: MDR September 2017 Quarterly Report & Appendix 4C, page-5

MDR is not a traders stock.
Solid over 10% in all indicators quarter on quarter growth. Just obout to reach 1M of patients. Penettrated 50% of pharmacy market.
Just deployed new integrated software with new futures.
Maximum size of Australian market 6M potential patients and $50M potential revenue.
Sooner or later we could expect some kind of collaboration with Medicare which means saving s for goverment, many benefits for patients and additional $$$$ for sherholders.
Potential expantion into UK and US markets next year.